Dichloroacetate / Ca+2 Cancer Research Results

DCA, Dichloroacetate: Click to Expand ⟱
Features:
Dichloroacetate (DCA) is a metabolic modulator that targets the altered metabolic state of cancer cells by inhibiting PDKs. This action impacts several key pathways:

• Reversal of the Warburg effect
• Restoration of mitochondrial function and promotion of apoptosis
• suppresses glycolysis and promotes oxidative phosphorylation, thereby increasing mitochondrial ROS-mediated apoptosis in tumor cells • Increase in ROS production leading to oxidative stress
• Inhibition of cell cycle progression
• Modulation of HIF-1α signaling: DCA might decrease HIF-1α stabilization, thereby reducing the expression of genes that support glycolysis, angiogenesis, and survival under low-oxygen conditions.

-DCA has been primarily used in treating congenital lactic acidosis—a rare genetic disorder characterized by the buildup of lactic acid in the body.
-DCA is an anti-diabetic and lipid-lowering drug, as well as treating myocardial and cerebrovascular ischemia.

-Do not add DCA to hot or warm beverages. DCA is unstable at higher temperatures
-Caffeinated increases effectiveness
-Vitamin B1 reduces neuropathy (500mg-2500mg/day)
-Possibly 20 grams of citric acid 20 minutes before taking DCA
-Procaine, Diclofenac or Sulindac to increase SMCT1
-Omeprazole 80mg/day to increase DCA effectiveness
-Scorpion venom to increase DCA effectiveness
-Metformin 1000mg to 1500mg/day
-Propranolol (Ref.)
-Fenbendazole shows strong synergy when combined to DCA, So it may make very much sense to combine the two.
"Note: DCA is not tumor cell specific,> and therefore the same shift in glucose metabolism that occurs in cancer cells will also take place in immune cells, leading to induction of Tregs (Ref.). In order to avoid this possibility, while using DCA I would also use Treg inhibitors such as Cimetidine (Ref.) or low dose Cyclophosphamide (Ref.)."

Dose: 10mg/kg/day and increase slowly to about 25mg/kg/day:(1/2morn,1/2evening) take 5 days on, 2 off? OR 2wks on/ 1wk off: https://www.thedcasite.com/dca_dosage.html
Done by mixing it in water and drinking, suggested that DCA not be taken on an empty stomach.

****
DCA-induced apoptosis in cancer cells requires sodium-coupled monocarboxylates transporter SLC5A8 (SMCT1)
-Inhibitors of DNA methylation induce reactivation of SLC5A8
-Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.
-SMCT1 was found to be stimulated by some other NSAIDs (diclofenac, meclofenamate and sulindac), by activin A143 and by the probiotic Lactobacillus plantarum.

SMCT1 has been found to be inhibited by some NSAIDs (ibuprofen, ketoprofen, fenoprofen, naproxen135 and indomethacin94), phytochemicals (resveratrol and quercetin) **** Hence these should be avoided with DCA. (also AVOID Bromide, iodide and sulfite )

****
GSTZ1 an/or chloride anion transport inhibitors also reduce resistance to DCA (if the tumor expresses GSTZ1 and contains a high chloride anions level, the GSTZ1 will be stable, maintaining the resistance to DCA).

-Dichloroacetate-dca-treatment-strategy GSTZ1 an/or chloride anion transport inhibitors. .
-Etacrynic acid is a Cl(-)-ATPase inhibitor
-Lansoprazole and Omeprazole inhibit chloride channels.
-Chlorotoxin found in scorpion venom (see my post on scorpion venom) can also inhibit chlorine channels

Sources:
https://northernhealthproducts.com/shop/
https://www.dcalab.com/

Rank Pathway / Target Axis Direction Primary Effect Notes / Cancer Relevance Ref
1 Pyruvate dehydrogenase kinase (PDK) → PDH gatekeeper ↓ PDK activity → ↑ active PDH (dephosphorylated) Warburg reversal (pyruvate into TCA) DCA’s canonical mechanism: inhibits PDK, restoring PDH activity and oxidative metabolism in cancer (ref)
2 Glycolysis output (lactate / ECAR) ↓ lactate production / ↓ ECAR Reduced acidification; metabolic reprogramming DCA decreases PDH phosphorylation and lowers glycolytic output (lactate/ECAR) in cancer models (ref)
3 Mitochondrial membrane potential remodeling (ΔΨm) ↓ cancer-associated mitochondrial hyperpolarization (depolarization) Restores apoptosis susceptibility Glioblastoma work: DCA reverses cancer-specific mitochondrial remodeling (hyperpolarization → depolarization), enabling apoptosis (ref)
4 ROS generation (especially under hypoxia) ↑ ROS Oxidative stress trigger DCA increases ROS in hypoxic cancer cells (reported strongly under hypoxia), linking metabolic shift to cytotoxic stress (ref)
5 Voltage-gated K+ channel axis (Kv1.5) / NFAT signaling ↑ Kv1.5 expression/activity Pro-apoptotic electrophysiology shift Endometrial cancer study: DCA engages mitochondrial + NFAT–Kv1.5 mechanisms associated with apoptosis sensitization (ref)
6 Intrinsic apoptosis (mitochondrial pathway) ↑ apoptosis Programmed cell death DCA induces apoptosis in glioblastoma and endometrial cancer models as mitochondrial remodeling is reversed (ref)
7 PUMA-mediated apoptotic priming ↑ PUMA-dependent sensitization Lower apoptotic threshold Endometrial cancer paper explicitly reports a PUMA-mediated component in DCA apoptosis sensitization (ref)
8 Hypoxia resistance axis (HIF-1α / PDK1) ↓ hypoxia-associated resistance (HIF-1α/PDK1 axis engaged) Improved treatment responsiveness DCA attenuates hypoxia-associated resistance in gastric cancer context with reported linkage to HIF-1α and PDK1 (ref)
9 Radiosensitization (hypoxic tumor cells) ↑ radiosensitivity (esp. under hypoxia) Therapy potentiation DCA increases ROS under hypoxia and enhances radiotherapy response in TNBC models (ref)
10 In vivo / translational anti-tumor activity (glioblastoma) ↓ tumor growth / ↓ proliferation (model-dependent) Demonstrated anti-tumor effect Glioblastoma study includes translational evidence that DCA can reverse tumor metabolic remodeling with anti-tumor effects (ref)


Ca+2, Calcium Ion Ca+2: Click to Expand ⟱
Source:
Type:
In all eukaryotic cells, intracellular Ca2+ levels are maintained at low resting concentrations (approximately 100 nM) by the activity of the major Ca2+ extrusion system, the plasma membrane Ca2+-ATPase (PMCA), which exchanges extracellular protons (H+) for cytosolic Ca2+.
Indeed, sustained elevation of [Ca2+]C in the form of overload, saturating all Ca2+-dependent effectors, prolonged decrease in [Ca2+]ER, causing ER stress response, and high [Ca2+]M, inducing mitochondrial permeability transition (MPT), are considered to be pro-death factors.
In cancer the Ca2+-handling toolkit undergoes profound remodelling (figure 1) to favour activation of Ca2+-dependent transcription factors, such as the nuclear factor of activated T cells (NFAT), c-Myc, c-Jun, c-Fos that promote hypertrophic growth via induction of the expression of the G1 and G1/S phase transition cyclins (D and E) and associated cyclin-dependent kinases (CDK4 and CDK2).
Thus, cancer cells may evade apoptosis through decreasing calcium influx into the cytoplasm. This can be achieved by either downregulation of the expression of plasma membrane Ca2+-permeable ion channels or by reducing the effectiveness of the signalling pathways that activate these channels. Such protective measures would largely diminish the possibility of Ca2+ overload in response to pro-apoptotic stimuli, thereby impairing the effectiveness of mitochondrial and cytoplasmic apoptotic pathways.
Voltage-Gated Calcium Channels (VGCCs): Overexpression of VGCCs has been associated with increased tumor growth and metastasis in various cancers, including breast and prostate cancer.
Store-Operated Calcium Entry (SOCE): SOCE mechanisms, such as STIM1 and ORAI1, are often upregulated in cancer cells, contributing to enhanced cell survival and proliferation.
High intracellular calcium levels are associated with increased cell proliferation and migration, leading to a poorer prognosis. Calcium signaling can also influence hormone receptor status, affecting treatment responses.
Increased Ca²⁺ signaling is associated with advanced disease and metastasis. Patients with higher CaSR expression may have a worse prognosis due to enhanced tumor growth and resistance to apoptosis. -Ca2+ is an important regulator of the electric charge distribution of bio-membranes.


Scientific Papers found: Click to Expand⟱
5196- DCA,    Dichloroacetate induces apoptosis in endometrial cancer cells
- in-vitro, Var, NA
selectivity↑, MMP↓, survivin↓, Ca+2↓, P53↑, PDK1↓, PDH↑, Glycolysis↓, OXPHOS↑, ROS↑, Cyt‑c↑, Apoptosis↑, Casp↑, tumCV↓, PUMA↑,
1877- DCA,    Non-Hodgkin′s Lymphoma Reversal with Dichloroacetate
- Case Report, lymphoma, NA
Remission↑, p‑PDKs↓, Glycolysis↓, i-Ca+2↓, toxicity↓, Dose∅,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

OXPHOS↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics

MMP↓, 1,  

Core Metabolism/Glycolysis

Glycolysis↓, 2,   PDH↑, 1,   PDK1↓, 1,   p‑PDKs↓, 1,  

Cell Death

Apoptosis↑, 1,   Casp↑, 1,   Cyt‑c↑, 1,   PUMA↑, 1,   survivin↓, 1,  

Transcription & Epigenetics

tumCV↓, 1,  

DNA Damage & Repair

P53↑, 1,  

Migration

Ca+2↓, 1,   i-Ca+2↓, 1,  

Drug Metabolism & Resistance

Dose∅, 1,   selectivity↑, 1,  

Functional Outcomes

Remission↑, 1,   toxicity↓, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Ca+2, Calcium Ion Ca+2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:288  Target#:38  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page